PRGO

#4422
Perrigo Company plc Ordinary Shares
0.1 1 USD
-3.57%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
0.11
0.11
1年のレンジ
0.11
22.01
1日の変化
-3.57%
月次変化
-99.02%
6か月変化
-99.17%
1年の変化
-99.49%
以前の終値
0.1 1
Open
0.1 1
安値
0.1 1
High
0.1 1
ボリューム
1 167
チャート全体を表示 Full chart

Financials

概要 明細書 統計 配当金
期次 年次
  • Market Capitalization 15.3 M
  • Employee 8 100
  • Founded N/A
  • CEO Murray S. Kessler
  • Website www.perrigo.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry 医薬品メーカー（特殊・ジェネリック）
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-0.74
売上高対価格比率
0.32
1株当たり配当金
0.29
配当利回り（％）
20.88

Perrigo Company plc Ordinary Shares

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.

ニュース